# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
– First Phase 3 HIV Prevention Trial to Show Zero Infections –– Independent Data Monitoring Committee Recommended That Gilead S...
Top performers last week were SRPT (+29.50%), SIRI (+16.73%), TOST (+15.57%), GILD (+12.62%), CHWY (+10.59%), ACN (+9.80%), DKN...
Stock market rally continues with new highs in S&P 500 and Nasdaq 100, driven by tech and semiconductor sectors, but concer...
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...
On Thursday before the market opened, Gilead announced efficacy data for its possible HIV prevention drug, Lenacapavir.